Speciallægens Høreklinik ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  15.3% 10.3% 8.3% 8.2% 6.5%  
Credit score (0-100)  14 24 28 29 35  
Credit rating  BB BB BB BB BBB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  1,231 1,117 2,699 2,229 1,997  
Gross profit  -93.5 16.9 84.1 259 244  
EBITDA  -93.5 16.9 84.1 259 244  
EBIT  -93.5 16.1 60.0 231 216  
Pre-tax profit (PTP)  -96.2 63.2 48.6 214.2 254.4  
Net earnings  -96.2 66.2 37.6 166.7 197.9  
Pre-tax profit without non-rec. items  -96.2 63.2 48.6 214 254  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 110 114 86.6 58.7  
Shareholders equity total  -46.2 20.0 57.6 224 422  
Interest-bearing liabilities  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  535 686 1,274 1,473 1,707  

Net Debt  -431 -462 -768 -897 -825  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  1,231 1,117 2,699 2,229 1,997  
Net sales growth  0.0% -9.2% 141.5% -17.4% -10.4%  
Gross profit  -93.5 16.9 84.1 259 244  
Gross profit growth  0.0% 0.0% 396.4% 207.6% -5.5%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  535 686 1,274 1,473 1,707  
Balance sheet change%  0.0% 28.2% 85.7% 15.6% 15.9%  
Added value  -93.5 16.9 84.1 254.8 244.3  
Added value %  -7.6% 1.5% 3.1% 11.4% 12.2%  
Investments  0 109 -20 -56 -56  

Net sales trend  0.0 -1.0 1.0 -1.0 -2.0  
EBIT trend  -1.0 1.0 2.0 3.0 4.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  -7.6% 1.5% 3.1% 11.6% 12.2%  
EBIT %  -7.6% 1.4% 2.2% 10.4% 10.8%  
EBIT to gross profit (%)  100.0% 95.1% 71.4% 89.2% 88.6%  
Net Earnings %  -7.8% 5.9% 1.4% 7.5% 9.9%  
Profit before depreciation and extraordinary items %  -7.8% 6.0% 2.3% 8.7% 11.3%  
Pre tax profit less extraordinaries %  -7.8% 5.7% 1.8% 9.6% 12.7%  
ROA %  -15.9% 10.0% 6.1% 16.9% 16.2%  
ROI %  0.0% 632.7% 140.8% 155.0% 78.0%  
ROE %  -18.0% 23.9% 96.9% 118.3% 61.2%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  -8.1% 2.9% 4.5% 15.2% 24.7%  
Relative indebtedness %  47.2% 59.6% 44.8% 55.6% 64.1%  
Relative net indebtedness %  12.2% 18.3% 16.3% 15.4% 22.8%  
Net int. bear. debt to EBITDA, %  461.4% -2,726.1% -913.5% -346.7% -337.7%  
Gearing %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 0.0% 0.0%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  0.9 0.9 0.8 0.9 0.9  
Current Ratio  0.9 0.9 1.0 1.1 1.3  
Cash and cash equivalent  431.3 461.6 767.9 896.6 825.0  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  29.1 27.4 20.8 32.4 50.6  
Trade creditors turnover (days)  374.2 391.2 111.5 40.1 65.1  
Current assets / Net sales %  43.5% 51.5% 43.0% 62.2% 82.5%  
Net working capital  -46.2 -416.2 -245.0 -35.3 321.7  
Net working capital %  -3.8% -37.3% -9.1% -1.6% 16.1%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0